Dupilumab listed on the PBS for severe asthma

Dupilumab (Dupixent) will be added to the PBS from Thursday, April 1 for adolescents from age 12 years and adults with uncontrolled severe type 2 asthma. The PBS listing of the monoclonal antibody, which targets both IL-4 and IL-13, will benefit an estimated 1,700 people with allergic or eosinophilic asthma. Commenting on the new indication, ...